Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: Results from the DANVIR cohort study

International Journal of Cancer

Volumn 130, Issue 10, 2012, Pages 2310-2317

  Omland, Lars Haukali ^a   Jepsen, Peter ^b   Krarup, Henrik ^c   Christensen, Peer Brehm ^d   Weis, Nina ^e   Nielsen, Lars ^f   Obel, Niels ^a   Sørensen, Henrik Toft ^b,g   Stuver, Sherri Oliver ^g  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f STATENS SERUM INSTITUT   (Denmark)

^g BOSTON UNIVERSITY   (United States)

Author keywords

HCV; hepatocellular carcinoma; non Hodgkin lymphoma

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; DENMARK; FEMALE; HEPATITIS C; HUMAN; LARGE CELL LYMPHOMA; LIVER CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; VIREMIA;

ADULT; CARCINOMA, HEPATOCELLULAR; CHILD; COHORT STUDIES; DENMARK; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LIVER NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RISK;

EID: 84859111069     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26283     Document Type: Article

References (43)

1. Simonetti RG, Cottone M, Craxi' A, Pagliaro L, Rapicetta M, Chionne P, Costantino A,. Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma. Lancet 1989; 334: 1338. (Pubitemid 20005713)
2. Colombo M, Kuo G, Choo QL, Donato MF, Del NE, Tommasini MA, Dioguardi N, Houghton M,. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 334: 1006-8. (Pubitemid 19257916)
3. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M, Bru C,. Prevalence of antibodies to hepatitis. C virus in. Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 334: 1004-6. (Pubitemid 19257915)
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M,. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62. (Pubitemid 19117877)
5. Amin J, Dore GJ, O'Connell DL, Bartlett M, Tracey E, Kaldor JM, Law MG,. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol 2006; 45: 197-203.
6. Omland LH, Farkas DK, Jepsen P, Obel N, Pedersen L,. Hepatitis C virus infection and risk of cancer: a population based cohort study. Clin Epidemiol 2010; 2: 179-86.
7. Strauss R, Torner A, Duberg AS, Hultcrantz R, Ekdahl K,. Hepatocellular carcinoma and other primary liver cancers in hepatitis C patients in Sweden-a low endemic country. J Viral Hepat 2008; 15: 531-7. (Pubitemid 351798991)
8. Omland LH, Krarup H, Jepsen P, Georgsen J, Harritshoj LH, Riisom K, Jacobsen SE, Schouenborg P, Christensen PB, Sorensen HT, Obel N,. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 36-42.
9. Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Hasegawa S, Oketani M, Ido A, Kusumoto K, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 2009; 50: 393-9.
10. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC,. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13: 5648-53. (Pubitemid 350031486)
11. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87. (Pubitemid 46453759)
12. Duberg AS, Nordstrom M, Torner A, Reichard O, Strauss R, Janzon R, Back E, Ekdahl K,. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005; 41: 652-9. (Pubitemid 40289514)
13. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA,. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007; 297: 2010-7. (Pubitemid 46740353)
14. Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S, Berndt SI, Ricker W, Parsons R, Wheeler W, Engels EA,. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 2008; 17: 3069-75.
15. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S, Talamini R, Holly EA, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-8. (Pubitemid 351447318)
16. Schollkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Panum I, Vinner L, Chang ET, Glimelius B, Porwit A, Sundstrom C, Hansen M, Adami HO, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008; 122: 1885-90. (Pubitemid 351413439)
17. Statistics Denmark. Available at:. http://www.statistikbanken.dk/ statbank5a/default.asp?w=1280 Accessed 25 Jan 2011.
18. The National Board of Health. Guide to the prevention of viral hepatitis [in Danish]. Available at:. http://www.sst.dk/publ/publ2002/hepatitis/html/hele. pdf. Accessed 25 Jan 2011.
19. Christensen PB, Krarup HB, Moller A, Laursen AL, Kjaer MS, Orholm M, Lindberg J, Groenbaek K, Kromann-Andersen H, Weis N,. Liver biopsy performance and histological findings among patients with chronic viral hepatitis: a Danish database study. Scand J Infect Dis 2007; 39: 245-9. (Pubitemid 46322809)
20. Lettmeier B, Muhlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, Siebert U,. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528-36.
21. Hansen N, Obel N, Christensen PB, Krarup H, Laursen AL, Clausen MR, Lunding S, Moller A, Schlichting P, Kromann-Andersen H, Bukh J, Weis N,. Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study. J Viral Hepat 2009; 16: 659-65.
22. The Central Office of Civil Registration. The Civil Registration System in Denmark. Available at:. http://www.cpr.dk/cpr/site.aspx?p=34 Accessed 25 Jan 2011.
23. Omland LH, Jepsen P, Krarup H, Schonning K, Lind B, Kromann-Andersen H, Homburg KM, Christensen PB, Sorensen HT, Obel N,. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 2011; 9: 71-8.
24. Krarup HB, Drewes AM, Madsen PH,. A quantitative HCV-PCR test for routine diagnostics. Scand J Clin Lab Invest 1998; 58: 415-22. (Pubitemid 28489470)
25. Omland LH, Jepsen P, Skinhoj P, Jorgensen HL, Munster AM, Bangsborg J, Fenger M, Sorensen HT, Obel N,. The impact of HIV-1 co-infection on long-term mortality in patients with hepatitis C: a population-based cohort study. HIV Med 2009; 10: 65-71.
26. Storm HH, Michelsen EV, Clemmensen IH, Pihl J,. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997; 44: 535-9.
27. The National Board of Health. The National Patient Registry. Available at:. http://www.sst.dk/Informatik-og-sundhedsdata/Registre-og-sundhedsstatistik/ Beskrivelse-af-registre/Landspatientregister.aspx?-lang=en2007 Accessed 25 Jan 2011.
28. Obel N, Reinholdt H, Omland LH, Engsig F, Sorensen HT, Hansen AB,. Retrivability in The Danish National Hospital Registry of HIV and hepatitis B and C coinfection diagnoses of patients managed in HIV centers 1995-2004. BMC Med Res Methodol 2008; 8: 25.
29. Omland LH, Jepsen P, Weis N, Christensen PB, Laursen AL, Nielsen H, Krarup H, Sorensen HT, Obel N,. Mortality in HIV-infected injection drug users with active vs. cleared hepatitis C virus-infection: a population-based cohort study. J Viral Hepat 2010; 17: 261-8.
30. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT,. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-36. (Pubitemid 351717418)
31. Engels EA, Frisch M, Lubin JH, Gail MH, Biggar RJ, Goedert JJ,. Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr 2002; 31: 536-41. (Pubitemid 35448662)
32. Lau B, Cole SR, Gange SJ,. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009; 170: 244-56.
33. Morton LM, Zheng T, Holford TR, Holly EA, Chiu BC, Costantini AS, Stagnaro E, Willett EV, Dal ML, Serraino D, Chang ET, Cozen W, et al. Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol 6: 469-76.
34. Pintille M,. Competing risks: a practical perspective, 1st ed. Wiley, Chichester, West Sussex, England, 2006.
35. WHO. World Health Organization (2004) Global status report on alcohol 2004-Country Profiles 2010.
36. Gentile I, Borgia G,. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010; 52: 778.
37. Bartosch B, Thimme R, Blum HE, Zoulim F,. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009; 51: 810-20.
38. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X,. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94. (Pubitemid 34753478)
39. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Berte R, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade. B-cell, non-Hodgkin's lymphoma: a multicenter. Italian experience. J Clin Oncol 2005; 23: 468-73. (Pubitemid 46224223)
40. Dal Maso L, Franceschi S,. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006; 15: 2078-85. (Pubitemid 44877029)
41. Machida K, Tsukiyama-Kohara K, Sekiguch S, Seike E, Tone S, Hayashi Y, Tobita Y, Kasama Y, Shimizu M, Takahashi H, Taya C, Yonekawa H, et al. Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins. Gastroenterology 2009; 137: 285-96.
42. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H,. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 2005; 43: 590-8. (Pubitemid 41253225)
43. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52. (Pubitemid 32634271)